{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T05:53:08Z","timestamp":1791611588156,"version":"4.3.4"},"reference-count":48,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T00:00:00Z","timestamp":1592956800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Human Mutation"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Farber disease and spinal muscular atrophy with progressive myoclonic epilepsy are a spectrum of rare lysosomal storage disorders characterized by acid ceramidase deficiency (ACD), resulting from pathogenic variants in N\u2010acylsphingosine amidohydrolase 1 (<jats:italic>ASAH1<\/jats:italic>). Other than simple listings provided in literature reviews, a curated, comprehensive list of <jats:italic>ASAH1<\/jats:italic> mutations associated with ACD clinical phenotypes has not yet been published. This publication includes mutations in <jats:italic>ASAH1<\/jats:italic> collected through the Observational and Cross\u2010Sectional Cohort Study of the Natural History and Phenotypic Spectrum of Farber Disease (NHS), <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:ext-link> identifier NCT03233841, in combination with an up\u2010to\u2010date curated list of published mutations. The NHS is the first to collect retrospective and prospective data on living and deceased patients with ACD presenting as Farber disease, who had or had not undergone hematopoietic stem cell transplantation. Forty\u2010five patients representing the known clinical spectrum of Farber disease (living patients aged 1\u201328 years) were enrolled. The curation of known <jats:italic>ASAH1<\/jats:italic> pathogenic variants using a single reference transcript includes 10 previously unpublished from the NHS and 63 that were previously reported. The publication of <jats:italic>ASAH1<\/jats:italic> variants will be greatly beneficial to patients undergoing genetic testing in the future by providing a significantly expanded reference list of disease\u2010causing variants.<\/jats:p>","DOI":"10.1002\/humu.24056","type":"journal-article","created":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T16:41:39Z","timestamp":1590424899000},"page":"1469-1487","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["<i>ASAH1<\/i> pathogenic variants associated with acid ceramidase deficiency: Farber disease and spinal muscular atrophy with progressive myoclonic epilepsy"],"prefix":"10.1155","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1400-8519","authenticated-orcid":false,"given":"Sarah H.","family":"Elsea","sequence":"first","affiliation":[{"name":"Molecular and Human Genetics Baylor College of Medicine Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Solyom","sequence":"additional","affiliation":[{"name":"Enzyvant Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirt","family":"Martin","sequence":"additional","affiliation":[{"name":"Molecular and Human Genetics Baylor College of Medicine Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Harmatz","sequence":"additional","affiliation":[{"name":"Pediatric Gastroenterolgy and Nutrition UCSF Benioff Children's Hospital Oakland Oakland California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Mitchell","sequence":"additional","affiliation":[{"name":"Montreal Children's Hospital Montreal Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Lampe","sequence":"additional","affiliation":[{"name":"UKGM Universit\u00e4tsklinikum Giessen Giessen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Grant","sequence":"additional","affiliation":[{"name":"Children's National Medical Center  Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila","family":"Selim","sequence":"additional","affiliation":[{"name":"Cairo University Children's Hospital Cairo Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neslihan Oneli","family":"Mungan","sequence":"additional","affiliation":[{"name":"Cukurova University Hospital Adana Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norberto","family":"Guelbert","sequence":"additional","affiliation":[{"name":"Children's Hospital of Cordoba Cordoba Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Magnusson","sequence":"additional","affiliation":[{"name":"Karolinska University Hospital Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Sundberg","sequence":"additional","affiliation":[{"name":"Karolinska University Hospital Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ratna","family":"Puri","sequence":"additional","affiliation":[{"name":"Sir Ganga Ram Hospital New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Kapoor","sequence":"additional","affiliation":[{"name":"Lok Nayak Hospital and Maulana Azad Medical College New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nur","family":"Arslan","sequence":"additional","affiliation":[{"name":"Dokuz Eylul University Hospital Izmir Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"DiRocco","sequence":"additional","affiliation":[{"name":"Metabolic Diseases Istituto Giannina Gaslini Genoa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha","family":"Zaki","sequence":"additional","affiliation":[{"name":"Clinical Genetics Department National Research Center Cairo Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seza","family":"Ozen","sequence":"additional","affiliation":[{"name":"Pediatric Rheumatology Hacettepe University Hospital Ankara Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iman G.","family":"Mahmoud","sequence":"additional","affiliation":[{"name":"Cairo University Children's Hospital Cairo Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karoline","family":"Ehlert","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsmedizin Greifswald Greifswald Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hahn","sequence":"additional","affiliation":[{"name":"UKGM Universit\u00e4tsklinikum Giessen Giessen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulden","family":"Gokcay","sequence":"additional","affiliation":[{"name":"Istanbul University Istanbul Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Torcoletti","sequence":"additional","affiliation":[{"name":"Pediatric Rheumatology University of Milan Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos R.","family":"Ferreira","sequence":"additional","affiliation":[{"name":"National Human Genome Research Institute National Institutes of Health Bethesda Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,6,24]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/emmm.201202301","article-title":"Systemic ceramide accumulation leads to severe and varied pathological consequences","volume":"5","author":"Alayoubi A. M.","year":"2013","journal-title":"EMBO Molecular Medicine"},{"key":"e_1_2_12_3_1","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.ymgme.2013.04.019","article-title":"Molecular basis of acid ceramidase deficiency in a neonatal form of Farber disease: Identification of the first large deletion in ASAH1 gene","volume":"109","author":"Alves M. Q.","year":"2013","journal-title":"Molecular Genetics and Metabolism"},{"key":"e_1_2_12_4_1","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S0022-3476(84)81106-3","article-title":"Phenotypic variability in siblings with Farber disease","volume":"104","author":"Antonarakis S. E.","year":"1984","journal-title":"Journal of Pediatrics"},{"key":"e_1_2_12_5_1","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1194\/jlr.D010033","article-title":"A simple fluorogenic method for determination of acid ceramidase activity and diagnosis of Farber disease","volume":"51","author":"Bedia C.","year":"2010","journal-title":"Journal of Lipid Research"},{"key":"e_1_2_12_6_1","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/s41431-018-0250-z","article-title":"A new case of SMA phenotype without epilepsy due to biallelic variants in ASAH1","volume":"27","author":"Beek N. A.","year":"2019","journal-title":"European Journal of Human Genetics"},{"key":"e_1_2_12_7_1","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.neurol.2015.06.002","article-title":"Myofibrillar myopathies: State of the art, present and future challenges","volume":"171","author":"Behin A.","year":"2015","journal-title":"Reviews in Neurology (Paris)"},{"key":"e_1_2_12_8_1","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1002\/art.39659","article-title":"Brief report: Peripheral osteolysis in adults linked to ASAH1 (Acid Ceramidase) mutations\u2014A new presentation of Farber's disease","volume":"68","author":"Bonafe L.","year":"2016","journal-title":"Arthritis & Rheumatology"},{"key":"e_1_2_12_9_1","doi-asserted-by":"crossref","first-page":"6493","DOI":"10.1038\/sj.onc.1204841","article-title":"The role of ceramide in receptor\u2010 and stress\u2010induced apoptosis studied in acidic ceramidase\u2010deficient Farber disease cells","volume":"20","author":"Burek C.","year":"2001","journal-title":"Oncogene"},{"key":"e_1_2_12_10_1","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s10545-015-9890-0","article-title":"Nervous system involvement in Farber disease","volume":"39","author":"Cappellari A. M.","year":"2016","journal-title":"Journal of Inherited Metabolic Disease"},{"key":"e_1_2_12_11_1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0009-8981(95)06173-8","article-title":"A simple method for screening for Farber disease on cultured skin fibroblasts","volume":"245","author":"Chatelut M.","year":"1996","journal-title":"Clinica Chimica Acta"},{"key":"e_1_2_12_12_1","doi-asserted-by":"crossref","first-page":"84","DOI":"10.15690\/vsp.v13i6.1207","article-title":"Farber disease\u2014Disease description with case reports","volume":"13","author":"Chikova I. A.","year":"2014","journal-title":"Current Pediatrics"},{"key":"e_1_2_12_13_1","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.bbadis.2016.11.031","article-title":"Acid ceramidase deficiency is characterized by a unique plasma cytokine and ceramide profile that is altered by therapy","volume":"1863","author":"Dworski S.","year":"2017","journal-title":"Biochimica et Biophysica Acta \u2010 Molecular Basis of Disease"},{"key":"e_1_2_12_14_1","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/cge.12307","article-title":"Evidence for clinical, genetic and biochemical variability in spinal muscular atrophy with progressive myoclonic epilepsy","volume":"86","author":"Dyment D. A.","year":"2014","journal-title":"Clinical Genetics"},{"key":"e_1_2_12_15_1","doi-asserted-by":"crossref","DOI":"10.1186\/1546-0096-5-15","article-title":"Farber disease: Clinical presentation, pathogenesis and a new approach to treatment","volume":"5","author":"Ehlert K.","year":"2007","journal-title":"Pediatric Rheumatology Online Journal"},{"key":"e_1_2_12_16_1","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/jimd.12043","article-title":"Allogeneic hematopoietic cell transplantation in Farber disease","volume":"42","author":"Ehlert K.","year":"2019","journal-title":"Journal of Inherited Metabolic Disease"},{"key":"e_1_2_12_17_1","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1096\/fj.06-7016com","article-title":"Acid ceramidase is a novel factor required for early embryo survival","volume":"21","author":"Eliyahu E.","year":"2007","journal-title":"FASEB Journal"},{"key":"e_1_2_12_18_1","first-page":"499","article-title":"A lipid metabolic disorder: Disseminated lipogranulomatosis; a syndrome with similarity to, and important difference from, Niemann\u2010Pick and Hand\u2010Schuller\u2010Christian disease","volume":"84","author":"Farber S.","year":"1952","journal-title":"The American Journal of Diseases of Children"},{"key":"e_1_2_12_19_1","first-page":"816","article-title":"Lipogranulomatosis; a new lipo\u2010glycoprotein storage disease","volume":"24","author":"Farber S.","year":"1957","journal-title":"Journal of the Mount Sinai Hospital, New York"},{"key":"e_1_2_12_20_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/TRD-160005","article-title":"Lysosomal storage diseases","volume":"2","author":"Ferreira C. R.","year":"2017","journal-title":"Translational Science of Rare Diseases"},{"key":"e_1_2_12_21_1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/8904_2013_246","article-title":"Accumulation of ordered ceramide\u2010cholesterol domains in farber disease fibroblasts","volume":"12","author":"Ferreira N. S.","year":"2014","journal-title":"JIMD Reports"},{"key":"e_1_2_12_22_1","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1038\/ejhg.2016.28","article-title":"ASAH1 variant causing a mild SMA phenotype with no myoclonic epilepsy: A clinical, biochemical and molecular study","volume":"24","author":"Filosto M.","year":"2016","journal-title":"European Journal of Human Genetics"},{"key":"e_1_2_12_23_1","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/BF00441558","article-title":"A case of combined Farber and Sandhoff disease","volume":"148","author":"Fusch C.","year":"1989","journal-title":"European Journal of Pediatrics"},{"key":"e_1_2_12_24_1","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.nmd.2015.09.007","article-title":"Acid ceramidase deficiency associated with spinal muscular atrophy with progressive myoclonic epilepsy","volume":"25","author":"Gan J. J.","year":"2015","journal-title":"Neuromuscular Disorders"},{"key":"e_1_2_12_25_1","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1016\/S0021-9258(18)51879-2","article-title":"Enzymic hydrolysis and synthesis of ceramides","volume":"238","author":"Gatt S.","year":"1963","journal-title":"Journal of Biological Chemistry"},{"key":"e_1_2_12_26_1","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.nmd.2014.11.007","article-title":"Uniparental disomy as a cause of spinal muscular atrophy and progressive myoclonic epilepsy: Phenotypic homogeneity due to the homozygous c.125C>T mutation in ASAH1","volume":"25","author":"Giraldez B. G.","year":"2015","journal-title":"Neuromuscular Disorders"},{"key":"e_1_2_12_27_1","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.bbacli.2017.02.001","article-title":"Enzyme replacement therapy for Farber disease: Proof\u2010of\u2010concept studies in cells and mice","volume":"7","author":"He X.","year":"2017","journal-title":"BBA Clinical"},{"key":"e_1_2_12_28_1","first-page":"1","article-title":"Why farber disease may be misdiagnosed as juvenile idiopathic arthritis","author":"Hugle B.","year":"2014","journal-title":"The Rheumatologist"},{"key":"e_1_2_12_29_1","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/hmg\/10.9.927","article-title":"A novel mutation in the coding region of the prosaposin gene leads to a complete deficiency of prosaposin and saposins, and is associated with a complex sphingolipidosis dominated by lactosylceramide accumulation","volume":"10","author":"Hulkova H.","year":"2001","journal-title":"Human Molecular Genetics"},{"key":"e_1_2_12_30_1","first-page":"116","article-title":"Hereditary myoclonus and progressive muscular atrophy: A new syndrome","volume":"103","author":"Jankovic J.","year":"1978","journal-title":"Transactions of the American Neurological Association"},{"key":"e_1_2_12_31_1","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s004310050603","article-title":"Hydrops fetalis: Manifestation in lysosomal storage diseases including Farber disease","volume":"156","author":"Kattner E.","year":"1997","journal-title":"European Journal of Pediatrics"},{"key":"e_1_2_12_32_1","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/humu.23211","article-title":"Whole\u2010transcriptome sequencing in blood provides a diagnosis of spinal muscular atrophy with progressive myoclonic epilepsy","volume":"38","author":"Kernohan K. D.","year":"2017","journal-title":"Human Mutation"},{"key":"e_1_2_12_33_1","doi-asserted-by":"crossref","first-page":"33110","DOI":"10.1074\/jbc.271.51.33110","article-title":"Molecular cloning and characterization of a full\u2010length complementary DNA encoding human acid ceramidase. Identification of the first molecular lesion causing Farber disease","volume":"271","author":"Koch J.","year":"1996","journal-title":"Journal of Biological Chemistry"},{"key":"e_1_2_12_34_1","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1006\/geno.1999.5940","article-title":"The human acid ceramidase gene (ASAH): Structure, chromosomal location, mutation analysis, and expression","volume":"62","author":"Li C. M.","year":"1999","journal-title":"Genomics"},{"key":"e_1_2_12_35_1","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1006\/geno.2002.6686","article-title":"Insertional mutagenesis of the mouse acid ceramidase gene leads to early embryonic lethality in homozygotes and progressive lipid storage disease in heterozygotes","volume":"79","author":"Li C. M.","year":"2002","journal-title":"Genomics"},{"key":"e_1_2_12_36_1","volume-title":"Metabolic basis of inherited diseases","author":"Moser H. W.","year":"1983"},{"key":"e_1_2_12_37_1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.seizure.2016.09.007","article-title":"Eyelid myoclonic status epilepticus: A rare phenotype in spinal muscular atrophy with progressive myoclonic epilepsy associated with ASAH1 gene mutation","volume":"42","author":"Oguz Akarsu E.","year":"2016","journal-title":"Seizure"},{"key":"e_1_2_12_38_1","unstructured":"Orphanet.2019. Retrieved fromhttps:\/\/www.orpha.net\/consor\/cgi-bin\/OC_Exp.php?Expert=333"},{"key":"e_1_2_12_39_1","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/epi.12977","article-title":"Spinal muscular atrophy associated with progressive myoclonic epilepsy: A rare condition caused by mutations in ASAH1","volume":"56","author":"Rubboli G.","year":"2015","journal-title":"Epilepsia"},{"key":"e_1_2_12_40_1","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s002920050148","article-title":"Disseminated lipogranulomatosis (Farber disease) with hydrops fetalis","volume":"17","author":"Schafer A.","year":"1996","journal-title":"Pathologe"},{"key":"e_1_2_12_41_1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF00694628","article-title":"A specific ultrastructural marker for disseminated lipogranulomatosis (Farber)","volume":"266","author":"Schmoeckel C.","year":"1979","journal-title":"Archives of Dermatological Research"},{"key":"e_1_2_12_42_1","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1080\/21678707.2017.1359086","article-title":"Morbidity and mortality associated with Farber disease and prospects for therapy","volume":"5","author":"Schuchman E. H.","year":"2017","journal-title":"Expert Opinion on Orphan Drugs"},{"key":"e_1_2_12_43_1","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.ajpath.2016.12.005","article-title":"Acid ceramidase deficiency in mice results in a broad range of central nervous system abnormalities","volume":"187","author":"Sikora J.","year":"2017","journal-title":"American Journal of Pathology"},{"key":"e_1_2_12_44_1","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-1068","article-title":"Polyarticular Arthritis And Spinal Muscular Atrophy In Acid Ceramidase Deficiency","volume":"138","author":"Teoh H. L.","year":"2016","journal-title":"Pediatrics"},{"key":"e_1_2_12_45_1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.clineuro.2017.11.008","article-title":"Spinal muscular atrophy with progressive myoclonic epilepsy linked to mutations in ASAH1","volume":"164","author":"Yildiz E. P.","year":"2018","journal-title":"Clinical Neurology and Neurosurgery"},{"key":"e_1_2_12_46_1","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-018-0845-z","article-title":"Acid ceramidase deficiency: Farber disease and SMA\u2010PME","volume":"13","author":"Yu F. P. S.","year":"2018","journal-title":"Orphanet Journal of Rare Disease"},{"issue":"10","key":"e_1_2_12_47_1","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1038\/s41374-019-0271-4","article-title":"Hepatic pathology and altered gene transcription in a murine model of acid ceramidase deficiency","volume":"99","author":"Yu F. P. S.","year":"2019","journal-title":"Laboratory Investigation"},{"key":"e_1_2_12_48_1","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1006\/mgme.2000.3029","article-title":"Human acid ceramidase gene: Novel mutations in Farber disease","volume":"70","author":"Zhang Z.","year":"2000","journal-title":"Molecular Genetics and Metabolism"},{"key":"e_1_2_12_49_1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ajhg.2012.05.001","article-title":"Spinal muscular atrophy associated with progressive myoclonic epilepsy is caused by mutations in ASAH1","volume":"91","author":"Zhou J.","year":"2012","journal-title":"American Journal of Human Genetics"}],"container-title":["Human Mutation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/humu.24056","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/humu.24056","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/humu.24056","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T06:45:33Z","timestamp":1759473933000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/humu.24056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,24]]},"references-count":48,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["10.1002\/humu.24056"],"URL":"https:\/\/doi.org\/10.1002\/humu.24056","archive":["Portico"],"relation":{},"ISSN":["1059-7794"],"issn-type":[{"value":"1059-7794","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6,24]]},"assertion":[{"value":"2019-11-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}